Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk
Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk
This study aimed to assess the correlation between the interleukin-10 (IL-10)-1082A/G
 polymorphism and idiopathic recurrent miscarriage (IRM) of Chinese Han. A total of 100 women
 with IRM and 100 control women with a successful pregnancy will be included in this study.
 Then genotyping will be performed.
As a common occurrence in early pregnancy, IRM has been associated with multiple causes,
 among which the disorders of immune homeostasis between the fetus and the maternal immune
 system, maintained by cytokines from the complex regulatory network, are considered one of
 the potential etiological factors underlying IRM.

 The IL-10 polymorphism -1082A/G (rs1800896), which is located in the promoter region of the
 IL-10 gene, was reported to be implicated in the abnormal expression of IL-10 in IRM by some
 studies.

 However, no such reports about the association between IL-10 polymorphism -1082A/G and IRM
 risk in Chinese Han.
Inclusion Criteria:

 1. women with more than three consecutive unexplained pregnancy losses before the 20th
 week;

 2. Chinese Han Population;

 3. Patients who signed informed consent.

 Exclusion Criteria:

 1. Patients who had other high-risk factors which might relate with recurrent
 miscarriage, including: (1) Parental karyotype abnormalities: significant
 rearrangements (e.g. balanced translocations and mosaics) were considered abnormal. If
 either the patient (or her partner) had an abnormal karyotype, it was considered a
 parental karyotypic abnormality; (2) Genital tract abnormalities: Any congenital
 anatomical deformation of the genital tract was considered abnormal; intrauterine
 adhesions, endometriosis and hydrosalpinx were also considered abnormal; (3)
 alloimmune disorder; (4) Endocrine abnormalities: prolactin (PRL) level >25 ng/ml,
 testosterone level >2.6 nmol/L, thyroid-stimulating hormone level <0.30 mU/L or >4.5
 mU/L, free thyroxine (FT4) level <8.36 nmol/L or >29.6 nmol/L and free
 triiodothyronine (FT3) level <1.84 nmol/L or >7.39 nmol/L. Glucose level > 126mg/dl;
 (5) Autoimmune disorders: Any positive results of Anti-cardiolipin antibodies
 (ACA-IgG/IgM/IgA), anti-nuclear antibodies (ANA-IgG), anti-endometrium antibodies
 (AEA-IgM), anti-ovary antibodies (AOA-IgM), anti-sperm antibodies (ASA-IgM),
 antithyroidin(TG-Ab), anti-thyroid peroxidase antibody(TPO-Ab) and/or anti-chorionic
 gonadotropin hormone antibody; (6) Hypercoagulation state: D-dimer levels >260 ng/ml,
 fibrin degradation products (FDP) levels >5 mg/L or anti-beta 2-glycoprotein I
 (anti-beta 2-GP1) levels >15 U/ml; (7) Negative RH blood groups; (8) Abnormal semen
 routine results of patients husband.

 2. Patients with serious diseases;

 3. Patients with administration of contraceptive pills;

 4. Patients participated in other randomized clinical research;

 5. Patients could not be followed-up of a long time or had poor compliance;

 6. Patients with other factors that would affect the study result.